Health
Alnylam Partners with Inceptive Nucleics for AI in RNAi Therapeutics
Biotech firm Alnylam entered into a three-year partnership with Inceptive Nucleics, valued at up to $2 billion. The deal includes an upfront payment of $30 million and equity stakes in the startup, aimed at advancing AI-driven RNAi therapeutics.
Coverage timeline — 2 articles
STAT News
Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
2026-06-03 20:45 UTC
STAT News
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
2026-06-03 20:45 UTC